ABSTRACT
A common genetic variant near MBOAT7 (rs641738C>T) has been previously associated with hepatic fat and advanced histology in non-alcoholic fatty liver disease (NAFLD), however, these findings have not been consistently replicated in the literature. Therefore, we aimed to establish whether rs641738 is a risk factor for NAFLD through meta-analysis. Data from 131,096 participants (7,692 with liver biopsies and 45,419 with imaging) was included in the meta-analysis. The minor T-allele of rs641738C>T was associated with higher liver fat on CT/MRI using an additive genetic model (+0.05 standard deviations [95% CI: 0.01 – 0.09], p=0.025), and with an increased risk of NAFLD (per-allele OR: 1.09 [95% CI: 1.01 - 1.17]), nonalcoholic steatohepatitis (OR: 1.11 [95% CI: 1.02 - 1.21]), advanced fibrosis (OR: 1.14 [95% CI: 1.05 - 1.23]), and hepatocellular carcinoma (OR: 1.43 [95% CI: 1.22 - 1.67]) in adults with NAFLD. Sub-group analysis did not demonstrate a difference in Caucasians and non-Caucasians. Rs641738C>T was not associated with markers of insulin resistance but was associated with higher risk of stroke in the UK Biobank. These data validate rs641738C>T near MBOAT7 as a risk factor for the development, activity, and stage of NAFLD including hepatocellular carcinoma.
Competing Interest Statement
Connor Emdin reports personal fees from Navitor Pharma and Novartis.
Clinical Protocols
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018105507
Funding Statement
JPM is supported by a Wellcome Trust Fellowship (216329/Z/19/Z) and a ChildrenÂ’s Liver Disease Foundation grant. NIH grants: R01HD028016 (SC), R01DK111038 (SC), R01DK114504 (NS), DK091601 (JKD), UL1TR001105 (JK). This study was supported by the German Federal Ministry for Education and Research (BmBF) through the Livers Systems Medicine (LiSyM) project. This work was supported by grants from the Swiss National Funds (SNF no. 310030_169196) and the Swiss Foundation for Alcohol Research (SSA) to FS. This Raine Study was supported by the National Health and Medical Research Council of Australia [grant numbers 403981, 353514 and 572613]. LV was supported by MyFirst Grant AIRC n.16888, Ricerca Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, LV and AG. received funding from the European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS- “Liver Investigation: Testing Marker Utility in Steatohepatitis”. KWMA & MH are supported by grants from MRC and Alcohol Research UK (MR/L022206/1). German Federal Ministry of Education and Research (BMBF LiSyM 031L0051 to F.L.) PL is supported by grants from the Sigrid Jusélius Foundation and the Novo Nordisk Foundation. The Fenland study was funded by grants to the MRC Epidemiology Unit (MC UU12015/1, MC UU 12015/5). RB and MK are employees of and shareholders in Perspectum Diagnostics Ltd. CAP is funded by a Wellcome Trust Clinical PhD Programme (206274/Z/17/Z).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contact information: Dr Jake P. Mann, University of Cambridge, Department of Paediatrics, Cambridge, United Kingdom. jm2032{at}cam.ac.uk, T: +44 1223 763480, F: +44 1223 336996
Financial support: JPM is supported by a Wellcome Trust Fellowship (216329/Z/19/Z) and a Children’s Liver Disease Foundation grant. NIH grants: R01HD028016 (SC), R01DK111038 (SC), R01DK114504 (NS), DK091601 (JKD), UL1TR001105 (JK). This study was supported by the German Federal Ministry for Education and Research (BmBF) through the Livers Systems Medicine (LiSyM) project. This work was supported by grants from the Swiss National Funds (SNF no. 310030_169196) and the Swiss Foundation for Alcohol Research (SSA) to FS. This Raine Study was supported by the National Health and Medical Research Council of Australia [grant numbers 403981, 353514 and 572613]. LV was supported by MyFirst Grant AIRC n.16888, Ricerca Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, LV and AG. received funding from the European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS- “Liver Investigation: KWMA & MH are supported by grants from MRC and Alcohol Research UK (MR/L022206/1). Testing Marker Utility in Steatohepatitis”. German Federal Ministry of Education and Research (BMBF LiSyM 031L0051 to F.L.) PL is supported by grants from the Sigrid Jusélius Foundation and the Novo Nordisk Foundation. The Fenland study was funded by grants to the MRC Epidemiology Unit (MC UU12015/1, MC UU 12015/5). RB and MK are employees of and shareholders in Perspectum Diagnostics Ltd. CAP is funded by a Wellcome Trust Clinical PhD Programme (206274/Z/17/Z).
Data Availability
Summary statistics available upon request.
Abbreviations (in order of appearance)
- NAFLD
- non-alcoholic fatty liver disease
- NAFL
- non-alcoholic fatty liver
- NASH
- non-alcoholic steatohepatitis
- HDL
- high-density lipoprotein
- HOMA-IR
- homeostatic model assessment of insulin resistance
- BMI
- body mass index
- ALT
- alanine aminotransferase
- CI
- confidence interval
- GGT
- gamma-glutamyl transferase
- OR
- odds ratio
- PNPLA3
- patatin-like phospholipase domain containing protein 3
- TM6SF2
- transmembrane 6 superfamily member 2
- TMC4
- transmembrane channel-like 4
- MBOAT7
- membrane bound O-acyltransferase domain containing 7.
